Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 215 participants.

Also called NCT03026933

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 215 participants (enrolled count) (from the registry)
Sponsor
Kuhnil Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT03026933
Other papers using this trial's data
  • Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial Clinical therapeutics, 2018-01 DOI, PubMed 29223557

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03026933. Randomized; double masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2016-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled
Acronym
ROMANTIC
Condition
Dyslipidemias
Intervention (Drug)
KI1107 4 Capsules, QD
Intervention (Drug)
Rosuvastatin Calcium 20 MG, QD
Lead sponsor
Kuhnil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03026933
Content hash
28c8923641a6993337916d205100009ae34e3bc0f4bd57e4fe903bc9bb09fd78